


IN THE CLAIMS

11. (AMENDED) A method of performing a phototherapeutic procedure which  
comprises:

(a) administering an effective amount of an organic azide  
photosensitizer having the formula



administer to  
whom?

wherein Ar is an aromatic or a heteroaromatic radical derived from benzenes, polyfluorobenzenes, naphthalenes, naphthoquinones, anthracenes, anthraquinones, phenanthrenes, tetracenes, naphthacenediones, pyridines, quinolines, isoquinolines, indoles, isoindoles, pyrroles, imidazoles, pyrazoles, pyrazines, purines, benzimidazoles, benzofurans, dibenzofurans, carbazoles, acridines, acridones, phenanthridines, thiophenes, benzothiophenes, dibenzothiophenes, xanthenes, xanthones, flavones, coumarins, and anthacylines; E is a hydrogen atom or is selected from the group consisting of somatostatin receptor binding molecules, ST receptor binding molecules, neurotensin receptor binding molecules, bombesin receptor binding molecules, CCK receptor binding molecules, steroid receptor binding molecules, and carbohydrate receptor binding molecules; L is selected from the group consisting of -  
 $(CH_2)_a-$ ,  $-(CH_2)_bCONR^1-$ ,  $-N(R^2)CO(CH_2)_c-$ ,  $-OCO(CH_2)_d-$ ,  $-(CH_2)_eCO_2-$ ,  $-OCONH-$ ,  $-OCO_2-$ ,  $-HNCONH-$ ,  $-HNCSNH-$ ,  $-HNNHCO-$ ,  $-OSO_2-$ ,  $-NR^3(CH_2)_eCONR^4-$ ,  $-CONR^5(CH_2)_fNR^6CO-$ , and  $-NR^7CO(CH_2)_gCONR^8-$ ; X is either a single bond or is

*a<sup>4</sup>*

selected from the group consisting of  $-(\text{CH}_2)_n-$ ,  $-\text{OCO}-$ ,  $-\text{HNCO}-$ ,  $-(\text{CH}_2)_l\text{CO}-$ , and  $-(\text{CH}_2)_j\text{OCO}-$ ;  $R^1$  to  $R^8$  are independently selected from the group consisting of hydrogen, C1-C10 alkyl, -OH, C1-C10 polyhydroxyalkyl, C1-C10 alkoxy, C1-C10 alkoxyalkyl,  $\text{SO}_3\text{H}$ ,  $-(\text{CH}_2)_k\text{CO}_2\text{H}$ , and  $-(\text{CH}_2)_l\text{NR}^9\text{R}^{10}$ ;  $R^9$  and  $R^{10}$  are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, and C1-C10 polyhydroxyalkyl; and subscripts a to l independently range from 0 to 10; and

(b) exposing said target tissues with the light at about 630 nm and 950 nm with sufficient power and fluence rate to perform the procedure.

*no antecedent basis  
for "said target  
tissues"*

Add the following new claims.

*a<sup>5</sup>*

21. (NEW) The method of claim 11 further comprising the step of allowing said photosensitizer to accumulate in said target tissue before exposing said tissue to light.

22. (NEW) The method of claim 11 wherein the photosensitizer is in a concentration ranging from about 1 nM to about 0.5 M.

23. (NEW) The method of claim 11 wherein the photosensitizer is in a concentration ranging from 1  $\mu\text{M}$  to 10 mM.

24. (NEW) The method of claim 11 wherein the photosensitizer is parenterally administered within a formulation including pharmaceutically acceptable substances

selected from the group consisting of buffers, emulsifiers, surfactants, electrolytes, and combinations thereof.

25. (NEW) The method of claim 11 wherein the photosensitizer is administered by a method selected from the group consisting of aerosol spray, cutaneously, parenterally, enterally, and topically.

26. (NEW) The method of claim 11 wherein the effective amount of the photosensitizer administered is in the range of 0.1 mg/kg body weight to 500 mg/kg body weight.

*a5*  
27. (NEW) The method of claim 11 wherein the effective amount of the photosensitizer administered is in the range of 0.5 mg/kg body weight to 2 mg/kg body weight.

---

Attached hereto is a marked-up version of the changes made by this Amendment. The attached page is captioned "Version with Markings to Show Changes Made."

**REMARKS**

Prior to examination, the specification has been amended to correct grammatical errors. Claims have been added to more completely define the invention. The amendments are fully supported in the Application as originally filed and contain no new matter.